safingol and Multiple Myeloma

safingol has been researched along with Multiple Myeloma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujimura, Y; Huang, Y; Kay, NE; Kim, YH; Kumazoe, M; Lesnick, C; Miura, D; Shanafelt, TD; Suzuki, T; Tachibana, H; Tsukamoto, S; Ueda, N; Yamada, S; Yamashita, S1
Alkan, S; Denning, MF; Ergin, M; Izban, KF; Ni, H; Tibudan, SS1

Other Studies

2 other study(ies) available for safingol and Multiple Myeloma

ArticleYear
Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Catechin; Cell Line, Tumor; Death-Associated Protein Kinases; Drug Synergism; Enzyme Activation; Female; Humans; Membrane Microdomains; Mice, Inbred BALB C; Multiple Myeloma; Phosphotransferases (Alcohol Group Acceptor); Receptor Protein-Tyrosine Kinases; Signal Transduction; Sphingomyelin Phosphodiesterase; Sphingosine; Xenograft Model Antitumor Assays

2015
Protein kinase C-delta is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis.
    British journal of haematology, 2003, Volume: 121, Issue:6

    Topics: Acetophenones; Apoptosis; Benzopyrans; Blotting, Western; Down-Regulation; Enzyme Inhibitors; Humans; Multiple Myeloma; Protein Kinase C; Protein Kinase C-delta; Sphingosine; Tumor Cells, Cultured

2003